Logo image of FENC

FENNEC PHARMACEUTICALS INC (FENC) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:FENC - CA31447P1009 - Common Stock

7.88 USD
+0.04 (+0.51%)
Last: 11/21/2025, 8:27:31 PM
7.88 USD
0 (0%)
After Hours: 11/21/2025, 8:27:31 PM
Fundamental Rating

3

Overall FENC gets a fundamental rating of 3 out of 10. We evaluated FENC against 533 industry peers in the Biotechnology industry. FENC has a bad profitability rating. Also its financial health evaluation is rather negative. FENC has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year FENC has reported negative net income.
In the past year FENC has reported a negative cash flow from operations.
FENC had negative earnings in each of the past 5 years.
FENC had negative operating cash flow in 4 of the past 5 years.
FENC Yearly Net Income VS EBIT VS OCF VS FCFFENC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

1.2 Ratios

FENC has a Return On Assets of -14.09%. This is amongst the best in the industry. FENC outperforms 81.12% of its industry peers.
Industry RankSector Rank
ROA -14.09%
ROE N/A
ROIC N/A
ROA(3y)-49.57%
ROA(5y)-56.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FENC Yearly ROA, ROE, ROICFENC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600 800

1.3 Margins

FENC has a Gross Margin of 93.12%. This is amongst the best in the industry. FENC outperforms 93.27% of its industry peers.
FENC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 93.12%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FENC Yearly Profit, Operating, Gross MarginsFENC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

3

2. Health

2.1 Basic Checks

Compared to 1 year ago, FENC has more shares outstanding
The number of shares outstanding for FENC has been increased compared to 5 years ago.
Compared to 1 year ago, FENC has an improved debt to assets ratio.
FENC Yearly Shares OutstandingFENC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
FENC Yearly Total Debt VS Total AssetsFENC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

FENC has an Altman-Z score of -2.58. This is a bad value and indicates that FENC is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -2.58, FENC perfoms like the industry average, outperforming 49.91% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.58
ROIC/WACCN/A
WACCN/A
FENC Yearly LT Debt VS Equity VS FCFFENC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 4.69 indicates that FENC has no problem at all paying its short term obligations.
With a Current ratio value of 4.69, FENC perfoms like the industry average, outperforming 53.27% of the companies in the same industry.
A Quick Ratio of 4.44 indicates that FENC has no problem at all paying its short term obligations.
FENC has a Quick ratio (4.44) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.69
Quick Ratio 4.44
FENC Yearly Current Assets VS Current LiabilitesFENC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for FENC have decreased strongly by -475.00% in the last year.
FENC shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -21.39%.
EPS 1Y (TTM)-475%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.48%
Revenue 1Y (TTM)-21.39%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%78.69%

3.2 Future

The Earnings Per Share is expected to grow by 240523.00% on average over the next years. This is a very strong growth
Based on estimates for the next years, FENC will show a very strong growth in Revenue. The Revenue will grow by 24.44% on average per year.
EPS Next Y-132665236383229020%
EPS Next 2Y10894974643.37%
EPS Next 3Y26121300%
EPS Next 5Y240523%
Revenue Next Year-21.01%
Revenue Next 2Y14.09%
Revenue Next 3Y15.4%
Revenue Next 5Y24.44%

3.3 Evolution

FENC Yearly Revenue VS EstimatesFENC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
FENC Yearly EPS VS EstimatesFENC Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

FENC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 11.96, the valuation of FENC can be described as reasonable.
Compared to the rest of the industry, the Price/Forward Earnings ratio of FENC indicates a rather cheap valuation: FENC is cheaper than 97.38% of the companies listed in the same industry.
FENC is valuated cheaply when we compare the Price/Forward Earnings ratio to 34.42, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 11.96
FENC Price Earnings VS Forward Price EarningsFENC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FENC Per share dataFENC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

A more expensive valuation may be justified as FENC's earnings are expected to grow with 26121300.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10894974643.37%
EPS Next 3Y26121300%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FENC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FENNEC PHARMACEUTICALS INC

NASDAQ:FENC (11/21/2025, 8:27:31 PM)

After market: 7.88 0 (0%)

7.88

+0.04 (+0.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2025-11-13/amc
Earnings (Next)03-09 2026-03-09/amc
Inst Owners56.74%
Inst Owner Change0.26%
Ins Owners2.21%
Ins Owner Change0.31%
Market Cap219.30M
Revenue(TTM)38.79M
Net Income(TTM)-6.94M
Analysts85.45
Price Target13.77 (74.75%)
Short Float %4.29%
Short Ratio9.51
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-95.59%
Min EPS beat(2)-199.56%
Max EPS beat(2)8.37%
EPS beat(4)2
Avg EPS beat(4)-67.7%
Min EPS beat(4)-199.56%
Max EPS beat(4)55.84%
EPS beat(8)3
Avg EPS beat(8)-157.9%
EPS beat(12)5
Avg EPS beat(12)-104.64%
EPS beat(16)6
Avg EPS beat(16)-92.56%
Revenue beat(2)1
Avg Revenue beat(2)3.98%
Min Revenue beat(2)-0.57%
Max Revenue beat(2)8.54%
Revenue beat(4)2
Avg Revenue beat(4)-10.17%
Min Revenue beat(4)-53.52%
Max Revenue beat(4)8.54%
Revenue beat(8)4
Avg Revenue beat(8)-7.28%
Revenue beat(12)6
Avg Revenue beat(12)2.86%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.17%
PT rev (3m)-2.17%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-28.69%
EPS NY rev (1m)0%
EPS NY rev (3m)-178.14%
Revenue NQ rev (1m)1.93%
Revenue NQ rev (3m)-0.54%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.42%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 11.96
P/S 5.65
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.23
EYN/A
EPS(NY)0.66
Fwd EY8.36%
FCF(TTM)-0.27
FCFYN/A
OCF(TTM)-0.27
OCFYN/A
SpS1.39
BVpS-0.16
TBVpS-0.16
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -14.09%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 93.12%
FCFM N/A
ROA(3y)-49.57%
ROA(5y)-56.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.79
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.69
Quick Ratio 4.44
Altman-Z -2.58
F-Score1
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-475%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.48%
EPS Next Y-132665236383229020%
EPS Next 2Y10894974643.37%
EPS Next 3Y26121300%
EPS Next 5Y240523%
Revenue 1Y (TTM)-21.39%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%78.69%
Revenue Next Year-21.01%
Revenue Next 2Y14.09%
Revenue Next 3Y15.4%
Revenue Next 5Y24.44%
EBIT growth 1Y-340.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2497.85%
EBIT Next 3Y306.35%
EBIT Next 5YN/A
FCF growth 1Y60.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y60.53%
OCF growth 3YN/A
OCF growth 5YN/A

FENNEC PHARMACEUTICALS INC / FENC FAQ

What is the ChartMill fundamental rating of FENNEC PHARMACEUTICALS INC (FENC) stock?

ChartMill assigns a fundamental rating of 3 / 10 to FENC.


What is the valuation status for FENC stock?

ChartMill assigns a valuation rating of 3 / 10 to FENNEC PHARMACEUTICALS INC (FENC). This can be considered as Overvalued.


How profitable is FENNEC PHARMACEUTICALS INC (FENC) stock?

FENNEC PHARMACEUTICALS INC (FENC) has a profitability rating of 2 / 10.


How financially healthy is FENNEC PHARMACEUTICALS INC?

The financial health rating of FENNEC PHARMACEUTICALS INC (FENC) is 3 / 10.